Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESG401 in Advanced/Metastatic Solid Tumors
NCT04892342Phase 2Completed
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd.
- Start
- Sep 2021
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ESG401 in solid tumor, metastatic solid tumor, breast cancer and 16 more (10 arms), sponsored by Shanghai Escugen Biotechnology Co., Ltd. Primary endpoints: Treatment Emergent Adverse Events and Objective Response Rate by Independent Central Review up to 49 months. Started Sep 2021; status: completed.
02
Drugs
ESG401
03
Conditions
solid tumormetastatic solid tumorbreast cancertriple negative breast cancer (TNBC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04892342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04892342.